■LERUP SSP®

KIR HLA Ligand Product Insert Page 1 of 17

104.201-12 – including *Taq* polymerase 104.201-12u – without *Taq* polymerase

Visit https://labproducts.caredx.com for "Instructions for Use" (IFU)

Lot No.: **0L4** Lot-specific information

Olerup SSP® KIR HLA Ligand

Product number: 104.201-12 – including *Taq* polymerase

104.201-12u - without *Taq* polymerase

Lot number: 0L4

Expiry date: 2024-03-01

Number of tests: 12 Number of wells per test: 7+1

Storage - pre-aliquoted primers: dark at -20°C

PCR Master Mix: -20°C
 Adhesive PCR seals RT
 Product Insert RT

This Product Description is only valid for Lot No. 0L4.

Complete product documentation consists of generic Instructions for Use (IFU), lot specific Product Insert, Worksheet and Certificate.

CHANGES COMPARED TO THE PREVIOUS OLERUP SSP® KIR HLA LIGAND LOT (8H1)

The product documentation has been updated for new alleles of IMGT 3.38.0

The KIR HLA Ligand specificity and interpretation tables have been updated for the HLA-A, HLA-B and HLA-C alleles described since the previous *Olerup* SSP® KIR HLA Ligand lot was made (Lot No. 8H1).

The KIR HLA Ligand primer set is unchanged compared to the previous *Olerup* SSP® KIR HLA Ligand (Lot No. 8H1).

104.201-12 – including *Taq* polymerase 104.201-12u – without *Taq* polymerase

Visit https://labproducts.caredx.com for "Instructions for Use" (IFU)

Lot No.: **0L4** Lot-specific information

Well **8** contains <u>Negative Control primer pairs</u>, that will amplify the majority of the *Olerup* SSP® HLA Class I, DRB, DQB1, DPB1 and DQA1 amplicons as well as all the amplicons generated by the control primer pairs matching the human growth hormone gene.

HLA-specific PCR product sizes range from 75 to 200 base pairs. The PCR product generated by the positive control primer pair is 200 base pairs.

Length of PCR	105	200	105	80	75	80	85
product							
5'-primer ¹	164	340	440	45	45	43	36
	5'-CAC3'	^{5'} -Agg ^{3'}	^{5'} -TTA3'	^{5'} -Tgg ^{3'}	^{5'} -Tgg ^{3'}	^{5'} -Tgg ^{3'}	^{5'} -TAC ^{3'}
							36
							^{5'} -TAT ^{3'}
3'-primer ²	231	2 nd I	507	59	58	57	47
	^{5'} -TgC ^{3'}	^{5'} -AAA ^{3'}	^{5'} -TTg ^{3'}	5'-CTC ^{3'}	^{5'} -ggC ^{3'}	^{5'} -CTC ^{3'}	5'-ACA3'
							48
							^{5'} -gCA ^{3'}
							48
							^{5'} -gCC ^{3'}
							52
A .II.							^{5'} -TgT ^{3'}
A *	+	+	+				
B*	+	+	+				
C*	+	+	+				
DRB1				+	+		
DRB3				+	+		
DRB5				+			
DQB1					+		
DPB1						+	
DQA1							+

¹The nucleotide position for HLA class I genes and the codon for HLA class II genes, in the 2nd or 3rd exon, matching the specificity-determining 3'-end of the primer is given. Nucleotide and codon numbering as on the www.ebi.ac.uk/imgt/hla web site. The sequence of the 3 terminal nucleotides of the primer is given.

²The nucleotide position for HLA class I genes and the codon for HLA class II genes, in the 2nd or 3rd exon or the 2nd intron, matching the specificity-determining 3'-end of the primer is given in the anti-sense direction. Nucleotide and codon numbering as on the www.ebi.ac.uk/imgt/hla web site. The sequence of the 3 terminal nucleotides of the primer is given.

(

Product Insert Page 3 of 17

104.201-12 – including *Taq* polymerase 104.201-12u – without *Taq* polymerase

Visit https://labproducts.caredx.com for "Instructions for Use" (IFU)

Lot No.: **0L4** Lot-specific information

PRODUCT DESCRIPTION

KIR HLA Ligand SSP typing

CONTENT

The primer set contains 5'- and 3'-primers for determining KIR HLA Ligand nucleotide sequence motifs;

HLA-A^{Bw4+} alleles,

HLA-B^{Bw4+} alleles encoding Isoleucine or Threonine at position 80,

HLA-B^{Bw4+} alleles encoding Aspartic acid at position 77 and Threonine at position 80.

HLA-B^{Bw6+} alleles encoding Asparagine at position 80,

HLA-C alleles encoding Asparagine or Lysine at position 80.

PLATE LAYOUT

Each test consists of 8 PCR reactions in an 8 well cut PCR plate.

1 2 3 4 5 6 7 NC

The 8 well cut PCR plate is marked with 'LIG' in silver/gray ink.

Well No. 1 is marked with the Lot Number '0L4'.

Wells 1 and 2: HLA-C KIR ligand primers.

Wells 3, 4, 6 and 7: HLA-B KIR ligand primers.

Well 5: HLA-A KIR ligand primers.

Well 8 – Negative Control (NC).

A faint row of numbers is seen between wells 1 and 2 or wells 7 and 8 of the PCR trays. These stem from the manufacture of the trays, and should be disregarded. The PCR plates are covered with a PCR-compatible foil.

Please note: When removing each 8 well PCR plate, make sure that the remaining plates stay covered. Use a scalpel or a similar instrument to carefully cut the foil between the plates.

UNIQUELY IDENTIFIED ALLELES

March 2020

Rev. No.: 00

The HLA-A, HLA-B and HLA-C alleles recognized by the HLA Nomenclature Committee in October 2019^{1,2,3} have been considered in the Specificity and Interpretation Tables.

 ϵ

¹A minor subset of rare B and C alleles with the listed target motifs will not be amplified by the kit due to downstream sequence variations.

²HLA-A, HLA-B and HLA-C alleles listed on the IMGT/HLA web page 2019-October-17, release 3.38.0, www.ebi.ac.uk/imgt/hla.

³Alleles that have been deleted from or renamed in the official WHO HLA Nomenclature up to and including the last IMGT/HLA database release can be retrieved from web page http://hla.alleles.org/alleles/deleted.html.

Product Insert Page 4 of 17

104.201-12 – including *Taq* polymerase 104.201-12u – without *Taq* polymerase

Visit https://labproducts.caredx.com for "Instructions for Use" (IFU)

Lot No.: **0L4** Lot-specific information

PROTOCOL

DNA EXTRACTION

Extracted, highly pure DNA is needed for SSP typings. DNA samples to be used for PCR-SSP HLA typing should be re-suspended in dH $_2$ O. The A260/A280 ratio should be 1.6 – 2.0 by UV spectrophotometry for optimal band visualization during electrophoresis.

We recommend automated DNA extraction with the QIAGEN EZ1 DSP DNA Blood System. ACD blood should be used as starting material.

Alternatively, the DNA can be extracted by any preferred method yielding pure DNA. When using alternative methods, the DNA concentration should be adjusted to 30 $ng/\mu l$. **Do not use heparinised blood with these methods.**

Recommended DNA concentration using:

EZ1-extracted DNA, 15 ng/μl.

DNA extracted by other methods, 30 ng/µl.

Concentrations exceeding 50 ng/ μ l will increase the risk for nonspecific amplifications and weak extra bands, especially for HLA Class I high resolution SSP typings. If necessary, dilute the extracted DNA in dH₂O.

DNA samples should not be re-suspended in solutions containing chelating agents such as EDTA, above 0.5 mM in concentration.

DNA samples may be used immediately after extraction or stored at +4°C for up to 2 weeks with no adverse effects on results. DNA samples can be stored at -20°C or colder for 9 months. The purity and concentration of extracted DNA samples that have been stored for a prolonged period should be tested for acceptability prior to HLA typing.

DNA samples should be shipped at +4°C or colder to preserve their integrity during transport.

PCR AMPLIFICATION

104.201-12 – including *Taq* polymerase

For one KIR HLA Ligand typing, begin by adding to well 8, i.e. the well with the negative control primer pairs:

7 μl dH₂O

3 μl PCR Master Mix complete with *Tag*,

then add at room temperature in a 0.5 ml tube:

 $9 \times 2 \mu I = 18 \mu I DNA (30 ng/\mu I)$

9 x 3 μ l = 27 μ l PCR Master Mix with Taq – mix well before taking your aliquot

 $9 \times 5 \mu I = 45 \mu I dH_2O$

(

March 2020 Rev. No.: 00 KIR HLA Ligand Product Insert Page 5 of 17

104.201-12 – including *Taq* polymerase 104.201-12u – without *Taq* polymerase

Visit https://labproducts.caredx.com for "Instructions for Use" (IFU)

Lot No.: **0L4** Lot-specific information

Mix well, dispense 10 μ l of the DNA-PCR Master Mix-H₂O mixture into each of the 7 wells of a KIR HLA Ligand typing, i.e. wells 1 to 7. Cover the primer tray(s) with the provided adhesive seals. Check that all reaction wells are completely covered to prevent evaporative loss during PCR amplification.

104.201-12u – without *Tag* polymerase

For one KIR HLA Ligand typing, begin by adding at room temperature in a 0.5 ml tube:

 $10 \times 3 \mu l = 30 \mu l$ PCR Master Mix without Taq – mix well before taking your aliquot

0,8 μl *Tag* polymerase (5 units/μl)

Mix well, dispense 3 μ l of the PCR Master Mix-Taq mixture from the 0.5 ml tube into well No. 8, i.e. the well with the negative control primer pairs. Then add 7 μ l dH₂O to well 8.

Then add at room temperature to the 0.5 ml tube containing 30 + 0.8 - 3 = 27.8 μ l PCR Master Mix-Taq mixture:

9 x 2
$$\mu$$
l = 18 μ l DNA (30 ng/ μ l)
9 x 5 μ l - 0.8 μ l = 44.2 μ l dH₂O

Mix well, dispense 10 μ l of the DNA-PCR Master Mix-Taq-H₂O mixture into each of the 7 wells of a KIR HLA Ligand typing, i.e. wells 1 to 7. Cover the primer tray(s) with the provided adhesive seals. Check that all reaction wells are completely covered to prevent evaporative loss during PCR amplification.

Use a 96 well thermal cycler with a heated lid. The temperature gradient across the heating block should be < 1°C.

PCR cycling parameters:

1. 1 cycle	94°C	2 min	denaturation
2. 10 cycles	94°C 65°C	10 sec. 60 sec.	denaturation annealing and extension
3. 20 cycles	94°C 61°C 72°C	10 sec. 50 sec. 30 sec.	denaturation annealing extension
4. End - hold	RT 4°C		if less than 8 hours if longer than 8 hours

Total reaction volume in each well, 10 µl.

The same PCR cycling parameters are used for all the *Olerup* SSP[®] kits.

AGAROSE GEL ELECTROPHORESIS

Prepare a 2% (w/v) agarose gel in 0.5 x TBE buffer. Dissolve the agarose by boiling in a microwave oven. Let the gel solution cool to 60°C. Stain the gel prior

KIR HLA Ligand Product Insert Page 6 of 17

104.201-12 – including *Taq* polymerase Visit https://labproducts.caredx.com for 104.201-12u – without *Taq* polymerase "Instructions for Use" (IFU)

Lot No.: **0L4** Lot-specific information

to casting with ethidium bromide (10 mg/ml), 5 μ l per 100 ml gel solution. For maximal ease of handling use our ethidium bromide dropper bottle (Product No. 103.301-10), 1 drop of ethidium bromide solution per 50-75 ml of gel, or our GelRedTM dropper bottle (Product No. 103.302-05) 4 drops per 100-120 ml of gel solution. Note: Ethidium bromide is a powerful carcinogen. Handle with appropriate personal protective equipment.

Load the PCR products, preferably using an 8-channel pipette. Load a DNA size marker (100 base pair ladder, Product No. 103.202-100 or DNA Size Marker for short gel runs 103.203-100) in one well per row.

Run the gel in 0.5 x TBE buffer, without re-circulation of the buffer, for 15-20 minutes at 8-10 V/cm.

DOCUMENTATION AND INTERPRETATION

Put the gel on a UV transilluminator and document by photography.

Record the presence and absence of specific PCR products. The relative lengths of the specific PCR products are helpful in the interpretation of the results.

Record the presence and relative lengths of the internal positive control bands. The differently sized control bands will help in the correct orientation of the typing as well as in kit identification.

Lanes without either control band or specific PCR products should be repeated.

Interpret the typings with the *lot-specific Interpretation and Specificity Tables*.

PCR MASTER MIXES

The PCR Master Mix complete with *Taq* polymerase contains:

Taq polymerase 0.4 unit per 10 μl SSP reaction

nucleotides final concentration of each dNTP is 200 μ M PCR buffer final concentrations: 50 mM KCl, 1.5 mM MgCl₂,

10 mM Tris-HCl pH 8.3, 0.001% w/v gelatin

glycerol final concentration of glycerol is 5%

cresol red final concentration of cresol red is 100 µg/ml

The same PCR Master Mix complete with Taq is used for all Olerup SSP® kits.

The PCR Master Mix without *Tag* polymerase contains:

nucleotides final concentration of each dNTP is 200 μ M PCR buffer final concentrations: 50 mM KCl, 1.5 mM MgCl₂,

10 mM Tris-HCl pH 8.3, 0.001% w/v gelatin

glycerol final concentration of glycerol is 5%

cresol red final concentration of cresol red is 100 µg/ml

The same PCR Master Mix without *Taq* is used for all *Olerup* SSP® kits.

Page 7 of 17

104.201-12 – including *Taq* polymerase 104.201-12u – without *Taq* polymerase

Visit https://labproducts.caredx.com for "Instructions for Use" (IFU)

Lot No.: **0L4** Lot-specific information

SPECIFICITY TABLE

KIR HLA Ligand SSP typing

Specificities and sizes of the PCR products of the 7+1 primer mixes used for KIR HLA Ligand SSP.

Primer Mix	Size of spec. PCR product ¹	Size of control band ²	KIR HLA Ligand nucleotide sequence motif	Amplified HLA alleles ^{3,4}
17	345 bp	800 bp	HLA-CAsn80	C*01:02:01:01-01:02:50, 01:02:52-01:13, 01:15:01-01:45, 01:47-01:153, 01:155-01:170, 01:172-01:187, 02:27:01-02:27:02, 02:65, 02:87, 02:115, 02:131, 03:02:01-03:06:02, 03:08-03:09, 03:11:01-03:11:02, 03:13:01:01-03:14, 03:16-03:28, 03:30-03:44, 03:46-03:98, 03:100-03:162, 03:164-03:267, 03:269-03:296:02, 03:298-03:394, 03:396N-03:398, 03:400-03:414, 03:416-03:437, 03:439-03:449N, 03:451-03:460, 03:462N-03:500, 03:502-03:504, 04:11, 04:29, 04:36, 04:55, 04:114, 04:172, 04:346, 04:383, 05:20, 06:11, 06:82, 06:147, 06:210, 06:217, 06:248, 06:252, 07:01:01:01-07:01:02:08, 07:01:04-07:02:77, 07:02:79-07:04:02:01, 07:04:03-07:06:03, 07:08, 07:10-07:33N, 07:35-07:75, 07:77-07:78:01, 07:79-07:114, 07:116-07:294, 07:296-07:314:03, 07:316-07:327, 07:329N-07:360, 07:362-07:405, 07:407-07:425, 07:427-07:458, 07:460-07:477, 07:479-07:558:01:02, 07:560-07:575:02, 07:577-07:597, 07:599-07:655, 07:657-07:672N, 07:674-07:715, 07:717-07:837, 08:01:01:01-08:09, 08:11-08:63, 08:65-08:145, 08:147-08:203, 08:205-08:206, 12:02:01-12:02:22, 12:02:24-12:03:61, 12:06-12:08, 12:10:01-12:20, 12:22-12:32, 12:34, 12:36-12:40, 12:42Q-12:59, 12:61-12:71, 12:73-12:134, 12:136-12:145, 12:147-12:153, 12:155Q-12:229, 12:231-12:304, 14:02:01:01-15:07:01:02, 15:25, 15:43, 15:85, 15:144, 15:181, 16:01:01-16:01:36, 16:04:01:01-16:04:01:03,

Page 8 of 17

104.201-12 – including *Taq* polymerase 104.201-12u – without *Taq* polymerase

Visit https://labproducts.caredx.com for "Instructions for Use" (IFU)

LOT	No.: UL4		ot-specific information	1
				16:04:03-16:04:05, 16:06-16:08, 16:10-16:11, 16:13-16:18, 16:20-16:24, 16:26-16:36, 16:38-16:45, 16:49-16:59, 16:61-16:62, 16:64-16:68, 16:71-16:73, 16:75-16:76, 16:78-16:83, 16:86-16:87, 16:92-16:93, 16:95-16:98, 16:100, 16:105-16:106, 16:109-16:114, 16:116-16:119, 16:122, 16:124-16:128, 16:130-16:131, 16:134-16:135, 16:137-16:139, 16:141-16:142, 16:146-16:152, 16:154, 16:157-16:162, 16:164, 17:22
28	350 bp	800 bp	HLA-CLys80	C*01:14, 01:154, 02:02:01- 02:02:03, 02:02:06-02:26:03, 02:28-02:40:02, 02:42-02:64, 02:66-02:86, 02:88-02:114, 02:116- 02:130, 02:132-02:186, 03:07:01:01-03:07:02, 03:10, 03:15, 03:29, 03:45, 03:163, 03:268, 03:297, 03:450, 03:461, 04:01:01:01-04:01:01:29, 04:01:01:31-04:01:120, 04:03:01:01-04:10, 04:12-04:20, 04:23-04:28, 04:30-04:35:02, 04:37-04:54:02, 04:56-04:113, 04:115N-04:171, 04:173N-04:249, 04:251-04:345, 04:347-04:382, 04:384-04:405, 05:01:01:01- 05:01:50, 05:03-05:19, 05:21- 05:227, 06:02:01:01-06:02:01:43, 06:02:03-06:10, 06:12-06:81, 06:83-06:146, 06:148-06:209, 06:211:01:01N-06:216, 06:218- 06:247, 06:249-06:251, 06:253- 06:292, 07:07, 07:09, 07:76:01- 07:76:02, 07:315, 07:328, 07:406, 07:559, 07:598, 07:656, 08:10, 12:04:01-12:05, 12:09, 12:21, 12:33, 12:41, 12:60, 12:72, 12:135, 12:146, 12:154, 14:12, 14:49, 14:108, 15:02:01:01-15:06:03, 15:08:01-15:13:01:02, 15:15-15:19, 15:21-15:24, 15:26-15:42, 15:44:01-15:84Q, 15:86-15:143, 15:145N-15:180, 15:182-15:207, 16:02:01:01-16:02:17, 16:09, 16:12, 16:19, 16:25, 16:37, 16:46-16:48, 16:60, 16:63, 16:69-16:70, 16:74, 16:77N, 16:84, 16:88-16:91, 16:99, 16:101-16:104, 16:107-16:108, 16:115, 16:120-16:121, 16:123N, 16:132N-16:133, 16:136, 16:140, 16:143-16:145, 16:153, 16:155- 16:156, 16:163, 17:01:01:02-17:21, 17:23-17:51:01:02, 18:01:01:01- 18:14

Page 9 of 17

104.201-12 – including *Taq* polymerase 104.201-12u – without *Taq* polymerase

Visit https://labproducts.caredx.com for "Instructions for Use" (IFU)

	10 UL T		specific information	D+0= 110 00 11 11 11
35	350 bp	800 bp	HLA-B ^{Bw4+Thr80}	B*07:149, 08:02, 08:117, 13:01:01:01-13:04, 13:06-13:08, 13:10-13:23, 13:25-13:38, 13:40-13:66, 13:68-13:139N, 15:36, 15:89:01-15:89:02, 15:115, 15:256, 15:339, 15:505, 18:09, 27:01, 27:142, 37:01:02, 37:10, 38:02:01:01-38:04, 38:08, 38:15, 38:18, 38:23, 38:29, 38:35, 38:43-38:50, 38:62, 38:64, 38:72, 38:74-38:76, 38:79, 38:82, 38:84-38:85, 38:160, 38:162, 40:47, 40:96, 40:110, 40:157, 40:201, 44:02:01:01-44:02:44, 44:02:46-44:05:02, 44:05:04, 44:07-44:08, 44:10-44:17, 44:19N-44:24, 44:26-44:45, 44:47-44:49, 44:51-44:74, 44:76-44:89, 44:91-44:94, 44:96-44:128:02, 44:130, 44:132-44:151, 44:153-44:169, 44:171N-44:195N, 44:197-44:245, 44:247-44:253, 44:255-44:256, 44:258-44:276, 44:278-44:344, 44:346, 44:437, 44:439-44:453, 44:456-44:480Q, 47:04, 49:02, 51:54, 51:78:01-51:78:02, 52:20, 53:09, 53:11-53:13, 53:31, 53:36, 53:38, 56:07, 59:08
4 ⁵	350 bp	1070 bp	HLA-B ^{Bw4+lle80}	B*07:36, 07:38, 07:81, 07:180, 07:219, 08:03, 08:52, 08:78, 15:13:01-15:13:02, 15:16:01:01-15:17:07, 15:23-15:24:02, 15:67, 15:87, 15:95, 15:157, 15:162, 15:168, 15:177, 15:196, 15:208, 15:216, 15:222, 15:230, 15:254, 15:268, 15:273, 15:356, 15:361-15:362, 15:396, 15:403, 15:408, 15:411, 15:418, 15:423-15:424, 15:442, 15:446, 15:462, 15:500, 15:516, 15:523, 15:532, 15:546Q, 15:550, 15:555, 18:67, 18:136, 27:02:01:01-27:02:05, 27:30, 27:53, 27:57, 27:62, 27:65N, 27:75, 27:77, 27:83, 27:95, 27:102, 27:119, 27:126, 27:134, 27:157, 27:163, 27:171-27:172, 27:176N, 27:181, 27:188, 27:197, 27:203, 27:213, 37:34, 38:01:01:01-38:01:16, 38:05-38:07, 38:09-38:14, 38:16, 38:19-38:22, 38:24-38:28, 38:30-38:34N, 38:36-38:42, 38:51-38:61, 38:63, 38:65-38:71, 38:73, 38:77-38:78, 38:80N-38:81, 38:83N, 38:86, 38:161, 40:13, 40:19, 40:109, 40:117, 40:292, 40:340, 40:394, 41:46, 41:60, 44:06, 44:18, 44:25, 44:50:01, 44:50:03, 44:95,

Page 10 of 17

104.201-12 – including *Taq* polymerase 104.201-12u – without *Taq* polymerase

Visit https://labproducts.caredx.com for "Instructions for Use" (IFU)

	LOT NO OLT		-specific information	
				48:18, 49:01:01:01-49:01:16, 49:03-49:14, 49:16-49:65, 51:01:01:01-51:24:05, 51:26-51:46, 51:48-51:53, 51:55-51:77, 51:79- 51:307, 52:01:01:01-52:01:28, 52:01:30-52:19, 52:21:01-52:94N, 53:01:01:01-53:02, 53:04-53:08:02, 53:10, 53:14-53:30, 53:32-53:35, 53:37, 53:39-53:54, 53:56-53:58, 54:12, 55:103, 56:21, 56:65, 57:01:01:01-57:11, 57:13-57:127, 58:01:01:01-58:02:02, 58:04- 58:16:02, 58:18-58:29, 58:31N- 58:63, 58:65-58:120, 59:01:01:01- 59:07, 59:09-59:10N
5	370 bp	1070 bp	HLA-A ^{Bw4+}	A*01:95, 01:289, 01:298, 02:81, 02:87, 02:112, 02:124, 02:129, 02:136, 02:571, 02:829, 03:152, 03:219, 11:178, 11:190, 23:01:01:01-23:68, 23:70-23:89, 23:91N-23:102, 24:02:01:01-24:03:04, 24:05:01-24:11N, 24:13:01-24:15, 24:17-24:18, 24:20:01:01-24:27, 24:29-24:43, 24:45N-24:64, 24:66-24:88, 24:90:01N-24:99, 24:101-24:108, 24:110-24:128, 24:130-24:210, 24:212-24:240N, 24:242-24:289, 24:291-24:372, 24:374-24:405, 24:407-24:423, 24:425N-24:470, 24:472-24:477, 25:01:01:01-25:58, 25:60-25:64, 29:13, 31:07-31:08, 31:10, 32:01:01:01-32:133N, 68:36
6	350 bp	1070 bp	HLA-B ^{Bw4+} , Thr80	B*07:27, 07:236, 07:273, 08:126, 15:43, 18:54, 27:03-27:05:36, 27:05:38-27:07:06, 27:09-27:11, 27:13-27:17, 27:19:01:01-27:21, 27:23-27:25, 27:27-27:29, 27:31-27:32, 27:34-27:39, 27:41, 27:52, 27:54-27:56, 27:58-27:61, 27:63-27:64N, 27:66N-27:74, 27:76, 27:78-27:82, 27:34-27:33, 27:154-27:33, 27:154-27:35, 27:64N-27:66N-27:74, 27:76, 27:78-27:82, 27:84-27:88, 27:90:01-27:94N, 27:96:01-27:101, 27:103-27:118, 27:120-27:125, 27:127-27:133, 27:135-27:141, 27:143-27:152, 27:154-27:155, 27:158-27:162, 27:164, 27:166-27:170, 27:173-27:175, 27:177-27:180, 27:182-27:187, 27:189-27:196, 27:198-27:202, 27:205-27:212N, 27:214-27:221, 35:329, 37:01:01:01-37:01:01:09, 37:01:03-37:04:02, 37:06:01-37:09, 37:12-37:13, 37:15-37:33N, 37:35-37:36, 37:38-37:66, 37:68-37:91, 38:17, 40:188, 44:257,

104.201-12 – including *Taq* polymerase 104.201-12u – without *Taq* polymerase

Visit https://labproducts.caredx.com for "Instructions for Use" (IFU)

	Lot No.: UL4		ot-specific informatio	11
				47:01:01:02-47:01:05, 47:05-47:10,
				53:03, 53:55, 55:90, 56:46
7	350 bp	1070 bp	HLA-B ^{Bw6+}	B*07:02:01:01-07:02:77, 07:02:79-
				07:26, 07:28-07:35, 07:37:01-
				07:37:02, 07:39-07:80, 07:82-
				07:148, 07:150-07:179, 07:181N-
				07:191, 07:193-07:218, 07:220-
				07:235, 07:237-07:272N, 07:274-
				07:395, 08:01:01:01-08:01:55,
				08:04:01-08:05, 08:07-08:51,
				08:53:01-08:77, 08:79-08:116,
				08:118-08:125, 08:127-08:130,
				08:132-08:135, 08:137-08:138,
				08:140-08:152, 08:154-08:156,
				08:158-08:249, 13:09, 13:39, 13:67,
				14:01:01:01-14:86, 15:01:01:01-
				15:01:04, 15:01:06-15:12:03,
				15:14-15:15:01:02, 15:18:01:01-
				15:21:01:02, 15:25:01:01-15:35,
				15:37-15:40:02, 15:42, 15:44-
				15:58, 15:60-15:66, 15:68-15:86,
				15:88, 15:90-15:94N, 15:96-15:99,
				15:101-15:114, 15:116-15:129,
				15:131-15:156, 15:158-15:161,
				15:163-15:167, 15:169-15:176,
				15:178-15:195, 15:197:01-15:207,
				15:209N-15:215, 15:217-15:221,
				15:223-15:229, 15:231-15:253,
				15:255, 15:257-15:267, 15:269-
				15:272N, 15:274-15:276, 15:278-
				15:338, 15:340-15:355, 15:357-
				15:360, 15:363:01-15:376, 15:378-
				15:395, 15:397-15:402, 15:404-
				15:407, 15:409-15:410, 15:412-
				15:417, 15:419-15:422, 15:425-
				15:429, 15:431-15:441, 15:443-
				15:445, 15:447-15:461, 15:463N-
				15:499, 15:501-15:504, 15:506-
				15:515, 15:517-15:522, 15:524-
				15:531, 15:533-15:545, 15:547-
				15:549N, 15:551-15:554, 15:556,
				18:01:01:01-18:08, 18:10-18:15,
				18:17N-18:53, 18:55-18:66, 18:68-
				18:135:01:02, 18:137-18:178,
				18:180-18:189, 27:08, 27:12:01:01-
				27:12:01:03, 27:18, 27:26, 27:33,
				27:40, 27:42, 27:44, 27:89, 27:153,
				27:165 ^w , 27:204, 35:01:01:01-
				35:01:38, 35:01:40-35:02:08,
				35:02:10-35:43:01, 35:43:03-35:72,
				35:74-35:221, 35:223-35:247,
				35:249-35:292, 35:294-35:328,
				35:330-35:423, 35:425-35:466,
				37:05, 37:11, 37:14 ^w , 37:37, 37:67,
				38:156-38:159, 39:01:01:01-
				39:01:01:12, 39:01:03:01-39:01:14,
				39:01:16-39:20, 39:22-39:103,

104.201-12 – including *Taq* polymerase 104.201-12u – without *Taq* polymerase

Visit https://labproducts.caredx.com for "Instructions for Use" (IFU)

Lot No.: **0L4** Lot-specific information

39:105-39:160, 40:01:01-40:12:02, 40:14:01-40:16:01:02, 40:18, 40:20:01:01-40:40. 40:42-40:46. 40:48-40:75, 40:77-40:95, 40:97-40:108, 40:111-40:116, 40:118N-40:156, 40:158-40:187, 40:189-40:200, 40:202-40:291N, 40:293-40:339, 40:341-40:393, 40:395-40:399N, 40:401-40:449, 41:01:01:01-41:25, 41:27-41:45N, 41:47-41:59, 41:61-41:63, 42:01:01:01-42:02:02, 42:04-42:21, 42:23-42:27, 44:09, 44:46, 44:75, 44:90, 44:129, 44:131, 44:254, 44:277, 44:438N, 45:01:01:01-45:15, 45:17-45:25, 46:01:01:01-46:81, 47:02, 47:03w, 48:01:01:01-48:17, 48:19-48:50, 50:01:01:01-50:02:01:02, 50:04-50:20, 50:31-50:69, 54:01:01:01-54:11, 54:13-54:41, 55:01:01:01-55:05, 55:07-55:89N, 55:91-55:102, 55:104-55:106, 56:01:01:01-56:06, 56:08-56:20:02, 56:22-56:45, 56:47-56:64, 56:66-56:71, 57:12, 58:64, 67:01:01-67:07, 73:01:01:01-73:02, 78:01:01:01-78:10, 81:01:01:01-81:09, 82:01:01:01-82:03, 83:01 86 **Negative Control**

¹Alleles are assigned by the presence of specific PCR product(s). However, the sizes of the specific PCR products may be helpful in the interpretation of KIR HLA Ligand SSP typings.

When the primers in a primer mix can give rise to HLA-specific PCR products of more than one length this is indicated if the size difference is more than 20 base pairs. Size differences of 20 base pairs or less are not given. For high resolution SSP kits, the alleles listed are specified according to amplicon length.

Nonspecific amplifications, i.e. a ladder or a smear of bands, may sometimes be seen. GC-rich primers have a higher tendency of giving rise to nonspecific amplifications than other primers.

PCR fragments longer than the control bands may sometimes be observed. Such bands should be disregarded and do not influence the interpretation of the SSP typings.

PCR fragments migrating faster than the control bands, but slower than a 400 bp fragment may be seen in some gel read-outs. Such bands can be disregarded and do not influence the interpretation of the SSP typings. Some primers may give rise to primer oligomer artifacts. Sometimes this phenomenon is an inherit feature of the primer pair(s) of a primer mix. More often it is due to other factors such as too low amount of DNA in the PCR reactions, taking too long time in setting up the PCR reactions, working at elevated room temperature or using thermal cyclers that are not pre-heated.

²The internal positive control primer pairs amplify segments of the human growth hormone gene. The internal positive control bands are 1070 or 800 base pairs respectively, well distribution as outlined in the table. Well number 1 contains the shorter, 800 bp, internal positive control band. The well distribution of the internal controls can help in orientation of the kit on gel photo, as well as allow for kit identification. In the presence of a specific amplification the intensity of the control band often decreases.

³For several HLA Class I alleles 1st and/or 4th exon(s) and beyond, as well as intron nucleotide sequences, are not available. In these instances it is not known whether some of the primers of the SSP sets are completely matched with the target sequences or not. Assumption is made that unknown sequences in these regions are conserved within allelic groups.

⁴A minor subset of rare B and C alleles with the listed target motifs will not be amplified by the kit due to downstream sequence variations.

⁵Primer mixes 3 and 4 may have tendencies of unspecific amplifications.



KIR HLA Ligand Product Insert Page 13 of 17

104.201-12 – including *Taq* polymerase 104.201-12u – without *Taq* polymerase

Visit https://labproducts.caredx.com for "Instructions for Use" (IFU)

Lot No.: **0L4** Lot-specific information

⁶Primer mix 8 contains a negative control, which will amplify the majority of HLA amplicons as well as the amplicons generated by the control primer pairs matching the human growth hormone gene. HLA-specific PCR product sizes range from 75 to 200 base pairs and the PCR product generated by the HGH positive control primer pair is 200 base pairs.

⁷This lot will not amplify the C*01:46 allele in primer mix 1.

⁸The alleles C*05:32 (80^{Arg}), C*15:60 (80^{Gln}) and C*15:71(80^{lle}) will be amplified in primer mix 2.

Abbreviations

w: might be weakly amplified.

Asn: asparagine Asp: aspartic acid Ile: isoleucine Lys: lysine Thr: threonine

(

Page 14 of 17

104.201-12 - including Taq polymerase 104.201-12u - without Tag polymerase

Visit https://labproducts.caredx.com for "Instructions for Use" (IFU)

Lot No.: **0L4** Lot-specific information

PRIMER SPECIFICATION

	T						1
Well No.	1	2	3	4	5	6	7
Length of spec.	345	350	350	350	370	350	350
PCR product							
Length of int.	800	800	800	1070	1070	1070	1070
pos. control ¹							
5'-primer(s) ²	1 st I						
	^{5'} -CgA ^{3'}	^{5'} -CgA ^{3'}	^{5'} -CAg ^{3'}	^{5'} -CAg ^{3'}	^{5'} -gCA ^{3'}	5' -CAg 3'	5' -CAg 3'
3'-primer(s) ³	310	312	309	309	317	310	311
	^{5'} -gTT ^{3'}	^{5'} -AgT ^{3'}	^{5'} -gTg ^{3'}	^{5'} -ATC ^{3'}	^{5'} -ggA ^{3'}	^{5'} -ggT ^{3'}	^{5'} -ggT ^{3'}
	311	312	312	312			
	^{5'} -gAT ^{3'}	^{5'} -AgT ^{3'}	^{5'} -gCC ^{3'}	^{5'} -gCA ^{3'}			
	311	312	313				
	^{5'} -ggT ^{3'}	^{5'} -AgT ^{3'}	^{5'} -Cgg ^{3'}				
	316		315				
	^{5'} -gCT ^{3'}		^{5'} -AgT ^{3'}				
Well No.	1	2	3	4	5	6	7

¹The internal positive control primer pairs amplify segments of the human growth hormone gene. The internal positive control bands are 1070 or 800 base pairs respectively, well distribution as outlined in the table. Well number 1 contains the shorter, 800 bp, internal positive control band. The well distribution of the internal controls can help in orientation of the kit on gel photo, as well as allow for kit identification. In the presence of a specific amplification the intensity of the control band often decreases.

²The nucleotide position matching the specificity-determining 3'-end of the primer is given. Nucleotide numbering as on the www.ebi.ac.uk/imgt/hla web site. The sequence of the 3 terminal nucleotides of the primer is given.

³The nucleotide position matching the specificity-determining 3'-end of the primer is given in the anti-sense direction. Nucleotide numbering as on the www.ebi.ac.uk/imgt/hla web site. The sequence of the 3 terminal nucleotides of the primer is given.

■LERUP SSP*
KIR HLA Ligand

104.201-12 – including *Taq* polymerase 104.201-12u – without *Taq* polymerase

Visit https://labproducts.caredx.com for "Instructions for Use" (IFU)

Page 15 of 17

Lot No.: **0L4** Lot-specific information

	CELL LINE VALIDATION SHEET										
	KIR	HLA Lig	an	d p	rin						
						١	Ne	<u> </u>			
				1	2	3	4	5	6	7	
			.:	7	2	33	4	22	9	7	
			Prod. No.:	201896201	201896202	201896203	201896204	201896205	201896206	201896207	
			ġ.	88	89	83	89	89	89	89	
			P	201	201	201	201	201	201	201	
	IHV	C cell line ¹									
1	9001			+	-	-	-	+	-	+	
2	9280	LK707		+	+	-	+	-	-	+	
3	9011	E4181324		+	-	-	+	-	-	-	
4	9275	GU373		+	+	-	+	-	-	+	
5	9009	KAS011		-	+	-	-	-	+	-	
6	9353	SM		+	-	-	+	-	-	+	
7	9020			-	+	-	-	-	-	+	
8	9025			-	+	-	-	-	-	+	
9	9026			+	-	-	+	-	-	-	
10		LKT3		+	-	-	-	+	-	+	
11		PITOUT		+	-	+	Ŀ	-	•	_	
12	9052			-	+	-	+	-	•	_	
13		JESTHOM		+	-	-	Ŀ	-	+	-	
14		OLGA		+	-	-	Ŀ	-	•	+	
15	9075			+	-	-	Ŀ	+	•	+	
16		SWEIG007		-	+	-	-	-	-	+	
17		CTM3953540		+	-	-	Ŀ	-	-	+	
18	9257	32367		+	-	-	Ŀ	-	-	+	
19		BM16		+	-	-	-	-	-	+	
20		SLE005		+	-	-	-	-	-	+	
21 22		AMALA		+	-	-	Ŀ	-	-	+	
23	9124	KOSE		+	÷	-		-	-	+	
24	9035			+	+	-	+	+	-	_	
25		IBW9		+	-	-	. T			+	
26		WT49		+	-	-	+	-	-	-	
27	9191	CH1007		+	+	_	+	+		+	
28		BEL5GB		+	+	+	÷	÷	-	÷	
29		MOU		+	÷	+	-	-	-	-	
30	9021			÷	+	÷	-	-	-	+	
31		DUCAF		-	+	-	-	-	-	+	
32	9297			-	+	-	-	-	-	+	
33		MT14B		+	-	-	-	-	-	+	
34	9104	DHIF		+	-	-	+	-	-	-	
35	9302	SSTO		-	+	+	-	+	-	-	
36	9024	KT17		+	+	-	-	-	-	+	
37	9065	HHKB		+	-	-	-	-	-	+	
38	9099	LZL		+	-	-	-	-	-	+	
39	9315	CML		+	+	-	-	-	+	+	
40		WHONP199		+	+	+	-	-	-	+	
41		H0301		+	-	-	-	-	-	+	
42		TAB089		+	-	-	-	-	-	+	
43		T7526		+	-	-	-	-	-	+	
44	9057			+	-	-	+	-	-	-	
45		SHJO		-	+	-	-	+	-	+	
46		SCHU		+	-	-	÷	-	-	+	
47	9045			+	+	-	+	-	-	-	
48	9303	TER-ND		+	+	+	-	-	-	+	

¹The provided cell line HLA specificities are retrieved from the http://www.ihwg.org/hla web site. The specificity of an individual cell line may thus be subject to change.

In primer solutions 1 to 4 one, two or three of the 3'-primers were not possible to test.

²The specificity of each primer solution in the kit has been tested against 48 well characterized cell line DNAs and where applicable, additional cell line DNAs.

Product Insert Page 16 of 17

104.201-12 – including *Taq* polymerase 104.201-12u – without *Taq* polymerase

Visit https://labproducts.caredx.com for "Instructions for Use" (IFU)

Lot No.: **0L4** Lot-specific information

TRADEMARKS USED IN THIS DOCUMENT/PRODUCT

Olerup SSP^{\otimes} is a registered trademark of CareDx AB. QiagenTM is a trademark of QIAGEN.

WARRANTY

CareDx AB warrants its products to the original purchaser against defects in materials and workmanship under normal use and application. CareDx AB's sole obligation under this warranty shall be to replace, at no charge, any product that does not meet the performance standards stated on the product specification sheet.

This warranty applies only to products that have been handled and stored in accordance with *CareDx* AB's recommendations, and does not apply to products that have been the subject of alternation, misuse, or abuse.

All claims under this warranty must be directed to *CareDx* AB in writing and must be accompanied by a copy of the purchaser's invoice. This warranty is in lieu of all other warranties, expressed or implied, including the warranties of merchantability and fitness for a particular purpose. In no case shall *CareDx* AB be liable for incidental or consequential damages.

This product may not be reformulated, repacked or resold in any form without the written consent of *CareDx* AB, Franzengatan 5, SE-112 51 Stockholm, Sweden. Handle all samples as if capable of transmitting disease. All work should be performed wearing gloves and appropriate protection.

GUARANTEE

CareDx AB guarantees that the primers in the Olerup SSP® typing trays have the specificities given in the lot-specific Specificity and Interpretation Tables of the product insert.

When stored at –20°C, the dried primers are stable for 48 months from the date of manufacture.

When stored at -20° C, the PCR Master Mix including Taq polymerase and the PCR Master Mix without Taq polymerase are stable for 51 months from the date of manufacture.



KIR HLA Ligand Product Insert Page 17 of 17

104.201-12 – including *Taq* polymerase 104.201-12u – without *Taq* polymerase

Visit https://labproducts.caredx.com for "Instructions for Use" (IFU)

Lot No.: **0L4** Lot-specific information

Addresses:

Manufacturer:

Caredx AB, Franzengatan 5, SE-112 51 Stockholm, Sweden.

Tel: +46-8-508 939 00 Fax: +46-8-717 88 18

E-mail: orders-se@caredx.com

Web page: https://labproducts.caredx.com/

Distributed by:

CareDx GmbH, Löwengasse 47 / 6, AT-1030 Vienna, Austria.

Tel: +43-1-710 15 00 **Fax:** +43-1-710 15 00 10 **E-mail:** orders-at@caredx.com

Web page: https://labproducts.caredx.com/

CareDx Lab Solutions Inc., 901 S. Bolmar St., Suite R, West Chester, PA 19382

Tel: 1-877-653-78171 **Fax:** 610-344-7989

March 2020

Rev. No.: 00

E-mail: orders-us@caredx.com

Web page: https://labproducts.caredx.com/

For information on CareDx distributors worldwide, contact CareDx GmbH.

(